NEVVI Medicare utilization intelligence
or

← back

Provider profile

HERMEL, DAVID MD

Hematology-Oncology · NPI 1043673734 · LA JOLLA, CA

1
Groups
50
Codes · 2024
99,345
Disclosed services

HERMEL, DAVID is a Hematology-Oncology in LA JOLLA, CA, a member of 1 medical group, who billed 50 distinct codes to Medicare Part B in 2024.

Groups: SCRIPPS HEALTH (LA JOLLA, CA)

Year: 2024 · 2023 · 2022 🔒

Provider overview · all codes · CY2024

99,345
disclosed services
50
codes billed to Medicare Part B
Prior year · CY2023 46,653 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9025 Injection, azacitidine, 1 mg
Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
J9299 Injection, nivolumab, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9271 Injection, pembrolizumab, 1 mg
J0185 Injection, aprepitant, 1 mg
J1561 Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg
J1626 Injection, granisetron hydrochloride, 100 mcg
Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
J0897 Injection, denosumab, 1 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J1100 Injection, dexamethasone sodium phosphate, 1 mg
Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
96413 Administration of chemotherapy into vein, 1 hour or less
96375 Injection of additional new drug or substance into vein
J3489 Injection, zoledronic acid, 1 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
J2919 Injection, methylprednisolone sodium succinate, 5 mg
96372 Injection of drug or substance under skin or into muscle
36591 Collection of blood sample from implanted device
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96415 Administration of chemotherapy into vein, each additional hour
J3480 Injection, potassium chloride, per 2 meq
96417 Administration of additional new drug or substance into vein, 1 hour or less
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
36430 Transfusion of blood or blood products
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
J3475 Injection, magnesium sulfate, per 500 mg
J3490 Unclassified drugs
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
J7030 Infusion, normal saline solution , 1000 cc
96361 Infusion into a vein for hydration, each additional hour
36415 Insertion of needle into vein for collection of blood sample
96523 Irrigation of implanted venous access drug delivery device
J1200 Injection, diphenhydramine hcl, up to 50 mg
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96411 Administration of additional new drug or substance into vein using push technique
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
96360 Infusion into a vein for hydration, 31-60 minutes
96377 Application of on-body injector for under skin injection
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
99239 Hospital discharge day management, more than 30 minutes
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.